Cardeas banks $34M round for PhII antibiotic

H.I.G. BioVentures has stepped up to lead a $34 million round for Seattle-based Cardeas Pharma, which is developing new antibiotics for drug-resistant bacterial infections. The money "will enable us to complete a Phase II safety and efficacy study of our aerosol combination antibiotics as adjunctive therapy to intravenous antibiotics in patients at high risk for multidrug resistant infections who are on a mechanical ventilator," said CEO Bruce Montgomery, a high profile figure in the Seattle biotech hub. Novo A/S, Avalon Ventures, Devon Park Bioventures and WRF Capital (Washington Research Foundation), as well as additional new investor Delphi Ventures joined the round. Release


Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.